<DOC>
	<DOCNO>NCT00289900</DOCNO>
	<brief_summary>This 12-week clinical trial participant mixed hyperlipidemia study effect MK-0524B lipids.The primary hypothesis MK-0524B ( dose MK-0524A coadministered simvastatin ) superior atorvastatin decrease low denisity lipoprotein cholesterol ( LDL-C ) /high-density lipoprotein cholesterol ( HDL-C ) ratio follow dose comparison : 2g/20 mg MK-0524B versus 10 mg atorvastatin , 2g/40 mg MK-0524B versus 20 mg atorvastatin , 2g/40 mg MK-0524B versus 40 mg atorvastatin , 2g/40 mg MK-0524B versus 80 mg atorvastatin .</brief_summary>
	<brief_title>Lipid Efficacy Safety Participants With Mixed Hyperlipidemia ( MK-0524B-024 )</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type V</mesh_term>
	<mesh_term>Lipidoses</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Participant 18 80 year age Mixed Hyperlipidemia LDLC 130 190 mg/dL Triglycerides 150 500 mg/dL Pregnant lactate woman , woman intend become pregnant Diabetes mellitus poorly control , newly diagnose , take new recently adjust antidiabetic therapy ( exception Â± 10 unit insulin ) Human immunodeficiency virus ( HIV ) positive Any follow within past 3 month : heart attack , stoke , heart bypass surgery , unstable angina , angioplasty Active chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>